Literature DB >> 9870418

The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus.

I Rychlík1, G Miltenberger-Miltenyi, E Ritz.   

Abstract

Type II diabetes mellitus has become the leading cause of end-stage renal failure in many countries of Western Europe. In all European countries, even in those with a relatively low prevalence of diabetic nephropathy, the number of patients with type II diabetes mellitus admitted for renal replacement therapy has recently increased continuously. Survival and medical rehabilitation of patients with type II diabetes on renal replacement therapy is significantly worse than in non-diabetic patients. It is obvious that in order to stem the tide, intense efforts are necessary (i) to inform the medical community about the renal risk of type II diabetes and the striking effectiveness of preventive measures, (ii) to provide better care for diabetic patients, and (iii) to reduce the high prevalence of diabetes in the population by modification of the Western life style.

Entities:  

Mesh:

Year:  1998        PMID: 9870418     DOI: 10.1093/ndt/13.suppl_8.6

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  4 in total

Review 1.  A glimpse of matrix metalloproteinases in diabetic nephropathy.

Authors:  X Xu; L Xiao; P Xiao; S Yang; G Chen; F Liu; Y S Kanwar; L Sun
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

2.  MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy.

Authors:  Qiang Wang; Youli Wang; Andrew W Minto; Jinhua Wang; Qun Shi; Xinmin Li; Richard J Quigg
Journal:  FASEB J       Date:  2008-08-20       Impact factor: 5.191

3.  Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies.

Authors:  Hui Zhang; Shimiao Zhu; Jing Chen; Yang Tang; Hailong Hu; Viswanathan Mohan; Radha Venkatesan; Jianmin Wang; Haiping Chen
Journal:  Diabetes Care       Date:  2012-06       Impact factor: 19.112

4.  Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: a possible role for adiponectin and miR-21?

Authors:  Martine C Morrison; Gopala K Yakala; Wen Liang; Peter Y Wielinga; Kanita Salic; Arianne van Koppen; Tushar Tomar; Robert Kleemann; Peter Heeringa; Teake Kooistra
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.